anti-BCMA CAR-T cell therapy

anti-BCMA CAR-T cell therapy is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target B-cell maturation antigen (BCMA), also known as TNFRSF17. BCMA is a cell surface receptor highly expressed on malignant plasma cells in multiple myeloma but absent on naive B cells and non-hematologic tissues, making it an ideal therapeutic target. The therapy involves the ex vivo genetic modification of a patient's own T cells to express a CAR construct that recognizes BCMA, typically followed by lymphodepleting chemotherapy and re-infusion of the engineered cells. The specific program developed by Shanghai Henlius Biotech (evaluated in trial CTR20191141) utilizes a fully human VH binder (FHVH33) coupled with a CD8 hinge/transmembrane domain, a 4-1BB co-stimulatory domain, and a CD3ζ activation domain. This architecture is intended to provide potent and durable anti-tumor activity while minimizing immunogenicity. While the broader class of anti-BCMA CAR-T therapies includes FDA-approved products like idecabtagene vicleucel and ciltacabtagene autoleucel, the Henlius asset is currently in early-phase clinical development for relapsed or refractory multiple myeloma (RRMM).

Other names

anti-BCMA CAR-T cell injectionBCMA-targeted CAR-T cell therapyanti-BCMA CAR-T